{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hirsutism/prescribing-information/topical-eflornithine/","result":{"pageContext":{"chapter":{"id":"4573c138-4cd9-557f-9ff3-297c6187958a","slug":"topical-eflornithine","fullItemName":"Topical eflornithine","depth":2,"htmlHeader":"<!-- begin field c8d19cd9-7a7e-4669-9f9c-ffb22d58a4d1 --><h2>Topical eflornithine</h2><!-- end field c8d19cd9-7a7e-4669-9f9c-ffb22d58a4d1 -->","summary":"","htmlStringContent":"<!-- begin item 4c8ffed4-adee-4ea8-8aba-5d86edb529ee --><!-- end item 4c8ffed4-adee-4ea8-8aba-5d86edb529ee -->","topic":{"id":"f7bb546f-c63b-5f36-8592-742d53a300ba","topicId":"6cd0021b-eeb7-4f76-9627-4f095658d33a","topicName":"Hirsutism","slug":"hirsutism","lastRevised":"Last revised in July 2020","chapters":[{"id":"7f1b7b92-6387-5893-b9c1-1b0fe5e6921f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ad41ddff-180c-5c56-9fa8-cfcaa4b301ac","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4e6e27c3-ace8-5785-bc5d-74954333ce03","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84d0d634-74f6-5808-8f94-da5030ec05c6","slug":"changes","fullItemName":"Changes"},{"id":"24cd5147-9eea-5049-abb9-bbff6b2e15e8","slug":"update","fullItemName":"Update"}]},{"id":"bccddc08-eaf5-58bc-b91c-222a0631380a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59efd74-c7e8-5a58-88a9-274b74de9cc7","slug":"goals","fullItemName":"Goals"},{"id":"3e4b60ae-49dd-58fa-8977-9a8f93804089","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fb5d6918-d9cd-57de-8ef8-09ac15afb519","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fb74a918-ba53-56c2-b640-6a8b38dd4d52","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0a97044d-161a-536d-99bd-e30a0b9553dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed166746-cb44-593f-aa91-2daa54e9df51","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"530429b5-0393-529c-874a-7270e7bccb64","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2c5b6cec-8e35-5953-a425-773d40af6f62","slug":"definition","fullItemName":"Definition"},{"id":"7c04b952-69e3-54ba-abf5-964402df757c","slug":"causes","fullItemName":"Causes"},{"id":"1ab4046f-c4e7-520f-893f-e09d2db4390d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"dce06012-6849-5ef4-ab2b-0c84dc64de89","slug":"complications","fullItemName":"Complications"}]},{"id":"0e4a9c3d-b4db-57a6-b036-9e01073ecafc","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a58667b3-2a20-5be2-81aa-4b35ba1bc423","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fc818766-2cdb-52a0-ad0e-7925d2deab29","slug":"assessment-for-an-underlying-cause","fullItemName":"Assessment for an underlying cause"},{"id":"3e40d667-a42d-56c7-a222-6eb858be7c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"684a1492-2308-5cae-b75d-1460cf238959","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb3e5264-aa93-5618-a326-1f9052e41577","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"61f39625-be0c-52a3-bdb4-7f1b9eaf0ffd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4573c138-4cd9-557f-9ff3-297c6187958a","slug":"topical-eflornithine","fullItemName":"Topical eflornithine"}]},{"id":"1d2fa7d5-926c-5ced-b5ff-0c103d1ddbbc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3154c9fd-0eb5-5ee3-8a69-a18ed1a66193","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"243b8cac-0f37-5266-bf46-8279e00461db","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5fab04c2-7dc7-5ebd-89cd-f693a3cd663f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b5b1cd8e-118a-5aab-bc89-4fa265c0b038","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d0d01f8a-60fc-5ef2-94a6-9d894ebe74d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74f5177a-4053-5623-b286-63a07a583386","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"34dca8b6-44ff-5ef5-8816-48aa07f93aff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"61f39625-be0c-52a3-bdb4-7f1b9eaf0ffd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"730bebac-6fa6-5088-a61d-ab31c38d1a2f","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 2170c4cc-9935-4dc9-96ce-aaef00fda96d --><h3>What should I advise a person using eflornithine?</h3><!-- end field 2170c4cc-9935-4dc9-96ce-aaef00fda96d -->","summary":"","htmlStringContent":"<!-- begin item af873ff3-9441-406a-afe8-aaef00fda944 --><!-- begin field de41c649-1fab-44a3-b976-aaef00fda96d --><ul><li><strong>Topical eflornithine (Vaniqa<sup>® </sup>11.5% cream) </strong>is licensed for the treatment of facial hirsutism. </li><li><strong>Advise that:</strong><ul><li>A thin layer of topical eflornithine should be applied to the affected area two times a day, at least eight hours apart. The manufacturer advises that application should be limited to the face and under the chin because efficacy has only been demonstrated for these areas. </li><li>Topical eflornithine should be rubbed in thoroughly; contact with eyes or mucous membranes (for example nose or mouth) should be avoided.</li><li>Cosmetics may be applied over the treated area 5 minutes after applying topical eflornithine, and the treated area should not be washed for 4 hours after application.</li><li>Other hair removal methods (such as shaving or waxing) may be used in conjunction with topical eflornithine. In such cases, the cream should be applied no sooner than five minutes after the use of the hair removal method because increased stinging or burning may otherwise occur.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field de41c649-1fab-44a3-b976-aaef00fda96d --><!-- end item af873ff3-9441-406a-afe8-aaef00fda944 -->","subChapters":[]},{"id":"c0743a16-adf9-5577-a838-9fa4351c68cc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7195aac8-8dbe-4461-93d8-aaef00fd83e5 --><h3>What are the contraindications and cautions for eflornithine?</h3><!-- end field 7195aac8-8dbe-4461-93d8-aaef00fd83e5 -->","summary":"","htmlStringContent":"<!-- begin item b27dd957-2e20-4962-8138-aaef00fd837f --><!-- begin field 3d466b63-35ce-4d29-bca7-aaef00fd83e5 --><ul><li><strong>The manufacturer advises that topical eflornithine should not be used in:</strong><ul><li>Pregnant women — the potential risk of topical eflornithine to human pregnancy is unknown.</li><li>Breastfeeding women — it is not known if topical eflornithine is excreted in human milk.</li><li>People under the age of 19 years — there are no data available to support the use of topical eflornithine in this age group.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>]</p><!-- end field 3d466b63-35ce-4d29-bca7-aaef00fd83e5 --><!-- end item b27dd957-2e20-4962-8138-aaef00fd837f -->","subChapters":[]},{"id":"f6e988cf-cb31-5e00-a81b-1d49efc57c25","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c25d9488-0ac6-4d91-a4d7-aaef01026399 --><h3>What are the adverse effects of eflornithine?</h3><!-- end field c25d9488-0ac6-4d91-a4d7-aaef01026399 -->","summary":"","htmlStringContent":"<!-- begin item 0c5736bc-7d70-46cd-a853-aaef0102636c --><!-- begin field f02cea17-a1f6-4394-aa8d-aaef01026399 --><ul><li><strong>Adverse effects </strong>are mostly skin related, mild in intensity, and resolve without discontinuation of topical eflornithine or initiation of medical treatment.<ul><li>The most frequently reported adverse effect is mild acne.</li><li>Other common adverse effects include pseudofolliculitis barbae; alopecia; stinging, burning, tingling, or dry skin; pruritus; erythema; skin irritation; rash; and folliculitis.</li><li>If skin irritation or intolerance develops, the frequency of application should be reduced temporarily to once a day. Stop treatment if irritation continues. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>] </p><!-- end field f02cea17-a1f6-4394-aa8d-aaef01026399 --><!-- end item 0c5736bc-7d70-46cd-a853-aaef0102636c -->","subChapters":[]},{"id":"f1b2723f-0561-5e29-b503-e30484013f53","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4c0c39e7-5beb-4503-a43e-aaef01026f7c --><h3>What drug interactions occur with eflornithine?</h3><!-- end field 4c0c39e7-5beb-4503-a43e-aaef01026f7c -->","summary":"","htmlStringContent":"<!-- begin item 84b0a9d8-5bd0-4f10-803e-aaef01026f57 --><!-- begin field d27db87a-1aca-4200-b4c9-aaef01026f7c --><ul><li>There are no known drug interactions with topical eflornithine — no interaction studies have been carried out.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>] </p><!-- end field d27db87a-1aca-4200-b4c9-aaef01026f7c --><!-- end item 84b0a9d8-5bd0-4f10-803e-aaef01026f57 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}